TY - JOUR
T1 - Preferences of Treatment Strategies among Women with Low-Risk DCIS and Oncologists
AU - Byng, Danalyn
AU - Retèl, Valesca P
AU - Engelhardt, Ellen G
AU - Groothuis-Oudshoorn, Catharina G M
AU - van Til, Janine A
AU - Schmitz, Renée S J M
AU - van Duijnhoven, Frederieke
AU - Wesseling, Jelle
AU - Bleiker, Eveline
AU - van Harten, Wim H
AU - On Behalf Of The Grand Challenge Precision Consortium, null
N1 - Funding:
This work was supported by Cancer Research UK and by KWF Kankerbestrijding (ref.
C38317/A24043).
PY - 2021/8/6
Y1 - 2021/8/6
N2 - As ongoing trials study the safety of an active surveillance strategy for low-risk ductal carcinoma in situ (DCIS), there is a need to explain why particular choices regarding treatment strategies are made by eligible women as well as their oncologists, what factors enter the decision process, and how much each factor affects their choice. To measure preferences for treatment and surveillance strategies, women with newly-diagnosed, primary low-risk DCIS enrolled in the Dutch CONTROL DCIS Registration and LORD trial, and oncologists participating in the Dutch Health Professionals Study were invited to complete a discrete choice experiment (DCE). The relative importance of treatment strategy-related attributes (locoregional intervention, 10-year risk of ipsilateral invasive breast cancer (iIBC), and follow-up interval) were discerned using conditional logit models. A total of n = 172 patients and n = 30 oncologists completed the DCE. Patient respondents had very strong preferences for an active surveillance strategy with no surgery, irrespective of the 10-year risk of iIBC. Extensiveness of the locoregional treatment was consistently shown to be an important factor for patients and oncologists in deciding upon treatment strategies. Risk of iIBC was least important to patients and most important to oncologists. There was a stronger inclination toward a twice-yearly follow-up for both groups compared to annual follow-up.
AB - As ongoing trials study the safety of an active surveillance strategy for low-risk ductal carcinoma in situ (DCIS), there is a need to explain why particular choices regarding treatment strategies are made by eligible women as well as their oncologists, what factors enter the decision process, and how much each factor affects their choice. To measure preferences for treatment and surveillance strategies, women with newly-diagnosed, primary low-risk DCIS enrolled in the Dutch CONTROL DCIS Registration and LORD trial, and oncologists participating in the Dutch Health Professionals Study were invited to complete a discrete choice experiment (DCE). The relative importance of treatment strategy-related attributes (locoregional intervention, 10-year risk of ipsilateral invasive breast cancer (iIBC), and follow-up interval) were discerned using conditional logit models. A total of n = 172 patients and n = 30 oncologists completed the DCE. Patient respondents had very strong preferences for an active surveillance strategy with no surgery, irrespective of the 10-year risk of iIBC. Extensiveness of the locoregional treatment was consistently shown to be an important factor for patients and oncologists in deciding upon treatment strategies. Risk of iIBC was least important to patients and most important to oncologists. There was a stronger inclination toward a twice-yearly follow-up for both groups compared to annual follow-up.
U2 - 10.3390/cancers13163962
DO - 10.3390/cancers13163962
M3 - Article
C2 - 34439126
SN - 2072-6694
VL - 13
JO - Cancers
JF - Cancers
IS - 16
ER -
